Bullish Moving Averages
0
Bearish Moving Averages
9
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Open Price
859.00Prev. Close
864.9500Volume
125434.00Value
105508809.10Fundamentals
Market Cap
13239.20
Price to Earnings
0.00
Price to Book Value
18.40
Dividend Yield
0.00
PE to Growth
0.00
Op Revenue TTM
0.00
Net Profit TTM
0.00
Cash From Operating Activity
498.26
Return on Equity %
-0.56
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
19 Sep, 2024
54.3
Week
62.5
Month
45.6
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
843.37
PIVOT
First Resistance
856.73
Second Resistance
872.32
Third Resistance
885.68
First Support
827.78
Second Support
814.42
Third Support
798.83
Relative Strength Index
47.92
Money Flow Index
47.97
MACD
MACD Signal
Average True Range
46.6
Average Directional Index
23.29
Rate of Change (21)
-16.78
Rate of Change (125)
Day Commodity Channel Index
-108.4
Day Williams %R
-84.3
BETA
1 Month
-0.43
3 Month
1 Year
3 Year
PRICE CHANGE ANALYSIS
↓ -7.59%
1 Week
Low
High
828.05
944
↓ -21.14%
1 Month
Low
High
821
1175.9
↑ 23.88%
3 Months
Low
High
725
1175.9
↑ 23.88%
6 Months
Low
High
725
1175.9
↑ 23.88%
1 Year
Low
High
725
1175.9
13 Sep 2024
Akums Drugs gets patent for formulation to manage sickle cell disease
Akums Drugs and Pharmaceuticals on Friday said it has received patent for a formulation for Sickle Cell Disease (SCD). The company has received a patent from India patent office for its room temperature stable oral suspension of Hydroxyurea, a formulation aimed at managing SCD. "Our constant endeavor is to work on affordable medicines for Orphan Drugs and reduce dependency on imported medicines ensuring patient safety from rare diseases with timely and necessary treatment," Akums Managing Director Sanjeev Jain said in a statement. SCD, a genetic blood disorder, leads to severe health complications such as anaemia, frequent pain episodes and other debilitating symptoms, affecting millions worldwide, especially in India and Africa. Akums said its formulation will come at a fraction of the cost of imported Hydroxyurea solution.
12 Sep 2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Order Passed U/S 250 Of The Income Tax Act, 1961 In Favor Of The Company.
Order passed U/s 250 of the Income Tax Act, 1961 in favor of the company
12 Sep 2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Grant Of Patent Certificate
Grant of Patent Certificate
04 Sep 2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Earnings / Analyst Conference Call held for limited reviewed un-audited financial results of Q1 FY25.
30 Aug 2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earnings/Analysts Conference Call held for limited reviewed un-audited financial results of Q1 FY25.
27 Aug 2024
Akums Drugs and Pharmaceuticals back in black with 42 crore standalone net profit for June quarter
The company reported a revenue of 317 crore for the period under review. Revenues were near flat on a y-o-y basis at 316 crore
26 Aug 2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication
24 Aug 2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Appointment Of Mr. Amrut Medhekar As Chief Executive Officer- CDMO Business
Appointment of Mr. Amrut Medhekar as Chief Executive Officer- CDMO Business
